8049.HK
Jilin Province Huinan Changlong Bio-pharmacy Company Limited Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
8049.HK Stock Summary
Top 10 Correlated ETFs
8049.HK
Top 10 Correlated Stocks
8049.HK
In the News
8049.HK Financial details
Company Rating
Buy
Market Cap
1.01B
Income
148.21M
Revenue
841.55M
Book val./share
-
Cash/share
-
Dividend
0.55
Dividend %
38.21%
Employees
848
Optionable
No
Shortable
Yes
Earnings
17 Apr 2024
P/E
3.65
Forward P/E
-
PEG
-1.14
P/S
1.06
P/B
0.51
P/C
-
P/FCF
-
Quick Ratio
1.79
Current Ratio
2.75
Debt / Equity
0.05
LT Debt / Equity
0.05
-
-
EPS (TTM)
0.24
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
5.43%
Revenue Q/Q
26.12%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
100%
Inst Own
-
Inst Trans
-
ROA
10%
ROE
14%
ROC
0.15%
Gross Margin
70%
Oper. Margin
28%
Profit Margin
26%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.06-2.05
52W High
-10%
52W Low
+80%
RSI
54
Rel Volume
1.44
Avg Volume
172.24K
Volume
248K
Perf Week
-1.1%
Perf Month
-4.76%
Perf Quarter
40.63%
Perf Half Y
45.16%
-
-
-
-
Beta
0.133
-
-
Volatility
0.05%, 0.12%
Prev Close
-2.7%
Price
1.8
Change
-1.64%
8049.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.15 | 1.11 | 1.26 | 1.5 | 0 | |
| Net income per share | 0.26 | 0.23 | 0.26 | 0.35 | 0 | |
| Operating cash flow per share | 0.24 | 0.27 | 0.38 | 0.36 | 0 | |
| Free cash flow per share | 0.16 | 0.09 | 0.22 | 0.34 | 0 | |
| Cash per share | 1.47 | 0.43 | 0.47 | 1.84 | 0 | |
| Book value per share | 2.21 | 2.4 | 2.59 | 2.88 | 0 | |
| Tangible book value per share | 2.21 | 2.33 | 2.58 | 2.78 | 0 | |
| Share holders equity per share | 2.21 | 2.4 | 2.59 | 2.88 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 455.22M | 575.17M | 539.55M | 430.44M | 0 | |
| Enterprise value | 320.19M | 549.55M | 484.66M | 317.24M | -271.74M | |
| P/E ratio | 3.15 | 4.54 | 3.77 | 2.22 | 0 | |
| Price to sales ratio | 0.7 | 0.92 | 0.76 | 0.51 | 0 | |
| POCF ratio | 3.44 | 3.8 | 2.51 | 2.11 | 0 | |
| PFCF ratio | 4.97 | 10.96 | 4.41 | 2.23 | 0 | |
| P/B Ratio | 0.37 | 0.43 | 0.37 | 0.27 | 0 | |
| PTB ratio | 0.37 | 0.43 | 0.37 | 0.27 | 0 | |
| EV to sales | 0.5 | 0.88 | 0.69 | 0.38 | -0.32 | |
| Enterprise value over EBITDA | 1.81 | 3.35 | 2.44 | 1.42 | -1.24 | |
| EV to operating cash flow | 2.42 | 3.63 | 2.25 | 1.56 | -0.86 | |
| EV to free cash flow | 3.5 | 10.47 | 3.96 | 1.65 | -0.96 | |
| Earnings yield | 0.32 | 0.22 | 0.27 | 0.45 | 0 | |
| Free cash flow yield | 0.2 | 0.09 | 0.23 | 0.45 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0.05 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0.03 | |
| Net debt to EBITDA | -0.76 | -0.16 | -0.28 | -0.51 | -1.24 | |
| Current ratio | 3.61 | 1.94 | 1.56 | 2.47 | 1.66 | |
| Interest coverage | 1.46K | 211.44 | 516.33 | 414.72 | 386.08 | |
| Income quality | 0.76 | 1.01 | 1.21 | 1.03 | 1.59 | |
| Dividend Yield | 0.06 | 0.03 | 0.05 | 0.07 | 0 | |
| Payout ratio | 0.2 | 0.13 | 0.18 | 0.15 | 1.91 | |
| Sales general and administrative to revenue | 0.1 | 0.27 | 0.13 | 0.12 | 0.13 | |
| Research and developement to revenue | 0.02 | 0.05 | 0.03 | 0.02 | 0 | |
| Intangibles to total assets | 0 | 0.02 | 0 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.31 | -0.65 | -0.43 | -0.06 | -0.1 | |
| Capex to revenue | -0.06 | -0.16 | -0.13 | -0.01 | -0.04 | |
| Capex to depreciation | -1.92 | -4.46 | -3.21 | -0.34 | -1.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.58 | 3.49 | 3.86 | 4.73 | 0 | |
| ROIC | 0.12 | 0.09 | 0.1 | 0.12 | 0.1 | |
| Return on tangible assets | 0.09 | 0.07 | 0.07 | 0.08 | 0.07 | |
| Graham Net | 1.33 | 0.22 | -0.02 | 1.21 | 0 | |
| Working capital | 1.01B | 392.45M | 318.08M | 1.05B | 475.85M | |
| Tangible asset value | 1.24B | 1.31B | 1.45B | 1.56B | 1.43B | |
| Net current asset value | 965.98M | 348.87M | 271.31M | 1.01B | 362.7M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.05 | |
| Average receivables | 480.1M | 427.39M | 407.11M | 425.32M | 225.51M | |
| Average payables | 33.13M | 38.59M | 46.98M | 58.51M | 68.13M | |
| Average inventory | 51.3M | 52.57M | 70.66M | 109.65M | 117.98M | |
| Days sales outstanding | 248.74 | 243.2 | 206.76 | 195.61 | 0 | |
| Days payables outstanding | 117.28 | 170.02 | 149.36 | 123.87 | 100.05 | |
| Days of inventory on hand | 170.21 | 219.37 | 251.13 | 250.79 | 145.96 | |
| Receivables turnover | 1.47 | 1.5 | 1.77 | 1.87 | 0 | |
| Payables turnover | 3.11 | 2.15 | 2.44 | 2.95 | 3.65 | |
| Inventory turnover | 2.14 | 1.66 | 1.45 | 1.46 | 2.5 | |
| ROE | 0.12 | 0.09 | 0.1 | 0.12 | 0.1 | |
| Capex per share | -0.07 | -0.18 | -0.17 | -0.02 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.44 | 0.25 | 0.45 | 0.35 | 0 | |
| Net income per share | 0.16 | 0.09 | 0.05 | 0.09 | 0 | |
| Operating cash flow per share | 0.08 | 0 | 0.13 | 0 | 0 | |
| Free cash flow per share | 0.08 | 0 | 0.13 | 0 | 0 | |
| Cash per share | 1.84 | 1.87 | 2.17 | 0 | 0 | |
| Book value per share | 2.88 | 2.88 | 2.86 | 0 | 0 | |
| Tangible book value per share | 2.78 | 0 | 2.85 | 0 | 0 | |
| Share holders equity per share | 2.88 | 2.88 | 2.86 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0.01 | 0 | 0 | |
| Market cap | 430.44M | 548.57M | 652.34M | 668.21M | 0 | |
| Enterprise value | 317.24M | 1.6B | 561.28M | 0 | -271.74M | |
| P/E ratio | 1.21 | 2.62 | 5.73 | 3.19 | 0 | |
| Price to sales ratio | 1.73 | 3.85 | 2.58 | 3.39 | 0 | |
| POCF ratio | 9.74 | 0 | 8.83 | 0 | 0 | |
| PFCF ratio | 9.74 | 0 | 8.83 | 0 | 0 | |
| P/B Ratio | 0.27 | 0.34 | 0.41 | 0 | 0 | |
| PTB ratio | 0.27 | 0.34 | 0.41 | 0 | 0 | |
| EV to sales | 1.28 | 11.21 | 2.22 | 0 | -1.09 | |
| Enterprise value over EBITDA | 4.29 | 23.78 | 14.06 | 0 | -8.2 | |
| EV to operating cash flow | 7.18 | 0 | 7.59 | 0 | 0 | |
| EV to free cash flow | 7.18 | 0 | 7.59 | 0 | 0 | |
| Earnings yield | 0.21 | 0.1 | 0.04 | 0.08 | 0 | |
| Free cash flow yield | 0.1 | 0 | 0.11 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0.05 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0.03 | |
| Net debt to EBITDA | -1.53 | 15.62 | -2.28 | 0 | -8.2 | |
| Current ratio | 2.47 | 0 | 2.75 | 0 | 1.66 | |
| Interest coverage | -340.52 | 2.59K | 22.64 | 2.25K | -25.5 | |
| Income quality | 0.5 | 0 | 2.6 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.06 | 0.11 | 0.04 | 0.11 | 0.24 | |
| Research and developement to revenue | 0.08 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0 | 0 | 0 | 0.02 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.21 | 2.46 | 1.81 | 0 | 0 | |
| ROIC | 0.05 | 0.03 | 0.02 | 0 | 0.01 | |
| Return on tangible assets | 0.04 | 0 | 0.01 | 0 | 0.01 | |
| Graham Net | 1.21 | 1.87 | 1.37 | 0 | 0 | |
| Working capital | 1.05B | 1.05B | 1.19B | 0 | 475.85M | |
| Tangible asset value | 1.56B | 0 | 1.6B | 0 | 1.43B | |
| Net current asset value | 1.01B | 1.05B | 1.14B | 0 | 362.7M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.05 | |
| Average receivables | 225.51M | 225.51M | 145.26M | 0 | 0 | |
| Average payables | 32.84M | 32.84M | 24.61M | 0 | 0 | |
| Average inventory | 66.49M | 66.49M | 56.76M | 0 | 0 | |
| Days sales outstanding | 163.56 | 0 | 103.31 | 0 | 0 | |
| Days payables outstanding | 84.52 | 0 | 50.42 | 0 | 83.15 | |
| Days of inventory on hand | 171.13 | 0 | 116.28 | 0 | 121.31 | |
| Receivables turnover | 0.55 | 0 | 0.87 | 0 | 0 | |
| Payables turnover | 1.06 | 0 | 1.78 | 0 | 1.08 | |
| Inventory turnover | 0.53 | 0 | 0.77 | 0 | 0.74 | |
| ROE | 0.06 | 0.03 | 0.02 | 0 | 0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
8049.HK Frequently Asked Questions
What is Jilin Province Huinan Changlong Bio-pharmacy Company Limited stock symbol ?
Jilin Province Huinan Changlong Bio-pharmacy Company Limited is a HK stock and trading under the symbol 8049.HK
What is Jilin Province Huinan Changlong Bio-pharmacy Company Limited stock quote today ?
Jilin Province Huinan Changlong Bio-pharmacy Company Limited stock price is $1.8 today.
Is Jilin Province Huinan Changlong Bio-pharmacy Company Limited stock public?
Yes, Jilin Province Huinan Changlong Bio-pharmacy Company Limited is a publicly traded company.
Company Profile
- Volume Average 172.24K
- Market Capitalization 1.01B
- Employee 848
- CEO Mr. Hong Zhang
- Headquarters Kowloon,HK
- IPO Date 2001-05-24
-
Website
https://www.jlchanglong.com 
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.
